BioMarin Pharmaceutical, Inc. (BMRN)
54.80
-0.10
(-0.17%)
USD |
NASDAQ |
Oct 09, 16:00
54.80
0.00 (0.00%)
After-Hours: 20:00
BioMarin Pharmaceutical Free Cash Flow (Quarterly) : 133.86M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 133.86M |
| March 31, 2026 | 199.73M |
| December 31, 2025 | 56.55M |
| September 30, 2025 | 334.94M |
| June 30, 2025 | 167.90M |
| March 31, 2025 | 157.63M |
| December 31, 2024 | 165.33M |
| September 30, 2024 | 200.30M |
| June 30, 2024 | 96.92M |
| March 31, 2024 | 12.87M |
| December 31, 2023 | -9.213M |
| September 30, 2023 | 112.23M |
| June 30, 2023 | 47.33M |
| March 31, 2023 | -98.70M |
| December 31, 2022 | -29.57M |
| September 30, 2022 | 121.85M |
| June 30, 2022 | 28.19M |
| March 31, 2022 | -76.11M |
| December 31, 2021 | -33.18M |
| September 30, 2021 | 76.70M |
| June 30, 2021 | 56.53M |
| March 31, 2021 | 85.26M |
| December 31, 2020 | -53.25M |
| September 30, 2020 | 66.05M |
| June 30, 2020 | -5.748M |
| Date | Value |
|---|---|
| March 31, 2020 | -59.21M |
| December 31, 2019 | -3.499M |
| September 30, 2019 | 35.53M |
| June 30, 2019 | -56.97M |
| March 31, 2019 | -83.62M |
| December 31, 2018 | 7.295M |
| September 30, 2018 | -2.659M |
| June 30, 2018 | -56.38M |
| March 31, 2018 | -72.67M |
| December 31, 2017 | -25.28M |
| September 30, 2017 | -4.19M |
| June 30, 2017 | -28.98M |
| March 31, 2017 | -149.53M |
| December 31, 2016 | -51.78M |
| September 30, 2016 | -36.46M |
| June 30, 2016 | -71.31M |
| March 31, 2016 | -216.66M |
| December 31, 2015 | -172.01M |
| September 30, 2015 | -47.41M |
| June 30, 2015 | -48.28M |
| March 31, 2015 | -181.81M |
| December 31, 2014 | -55.98M |
| September 30, 2014 | -33.95M |
| June 30, 2014 | -52.06M |
| March 31, 2014 | -51.05M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| Ascendis Pharma A/S | 323.81M |
| Alnylam Pharmaceuticals, Inc. | 292.04M |
| Vertex Pharmaceuticals, Inc. | 1.013B |
| BridgeBio Pharma, Inc. | -71.54M |
| ACADIA Pharmaceuticals, Inc. | 95.69M |